NASDAQ:ALGS
Aligos Therapeutics Inc. Stock News
$0.81
-0.0359 (-4.24%)
At Close: May 03, 2024
Aligos Therapeutics, Inc. (ALGS) Just Flashed Golden Cross Signal: Do You Buy?
10:56am, Wednesday, 27'th Mar 2024
After reaching an important support level, Aligos Therapeutics, Inc. (ALGS) could be a good stock pick from a technical perspective. ALGS recently experienced a "golden cross" event, which saw its 50-
Aligos Therapeutics to Announce 4th Quarter 2023 Financial Results on March 12, 2024
04:05pm, Tuesday, 05'th Mar 2024
SOUTH SAN FRANCISCO, Calif., March 05, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on developing novel therapeut
Is Aligos Therapeutics (ALGS) Stock Outpacing Its Medical Peers This Year?
11:18am, Friday, 05'th Jan 2024
Here is how Aligos Therapeutics, Inc. (ALGS) and Allogene Therapeutics (ALLO) have performed compared to their sector so far this year.
Aligos Therapeutics To Present at the Piper Sandler Healthcare Conference
04:05pm, Monday, 20'th Nov 2023
SOUTH SAN FRANCISCO, Calif., Nov. 20, 2023 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on developing novel therapeuti
Why Is Aligos Therapeutics (ALGS) Stock Down 5% Today?
09:10am, Monday, 20'th Nov 2023
Aligos Therapeutics (NASDAQ:ALGS) stock is falling on Monday after the clinical-stage biopharmaceutical company announced plans for a porposed public share offering. According to a filing with the Sec
SOUTH SAN FRANCISCO, Calif., June 07, 2023 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address
Aligos Therapeutics to Present at the Jefferies 2023 Healthcare Conference
05:26pm, Wednesday, 24'th May 2023
SOUTH SAN FRANCISCO, Calif., May 24, 2023 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address u
Aligos Therapeutics, Inc. (ALGS) Reports Q1 Loss, Lags Revenue Estimates
08:30pm, Thursday, 04'th May 2023
Aligos Therapeutics, Inc. (ALGS) came out with a quarterly loss of $0.53 per share versus the Zacks Consensus Estimate of a loss of $0.49. This compares to loss of $0.84 per share a year ago.
Aligos Therapeutics to Announce First Quarter Results on May 4, 2023
04:05pm, Thursday, 27'th Apr 2023
SOUTH SAN FRANCISCO, Calif., April 27, 2023 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”, the “Company”), a clinical stage biopharmaceutical company focused on develop
SOUTH SAN FRANCISCO, Calif., April 11, 2023 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address
Aligos Therapeutics, Inc. (ALGS) Reports Q4 Loss, Tops Revenue Estimates
07:49pm, Thursday, 09'th Mar 2023
Aligos Therapeutics, Inc. (ALGS) delivered earnings and revenue surprises of -4.08% and 26.32%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the
Aligos Therapeutics to Present at the SVB Securities Global Biopharma Conference
07:00am, Friday, 10'th Feb 2023
SOUTH SAN FRANCISCO, Calif., Feb. 10, 2023 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address
4 Penny Stocks To Buy According To Analysts & Targets Over 600%
09:33am, Wednesday, 25'th Jan 2023
Analysts have put these on their list of penny stocks to buy. Do you agree?
4 Penny Stocks To Buy According To Insiders & Targets Up To 347%
09:29am, Thursday, 19'th Jan 2023
Penny stocks to buy according to analysts. The post 4 Penny Stocks To Buy According To Insiders & Targets Up To 347% appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.co
SOUTH SAN FRANCISCO, Calif., Oct. 21, 2022 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address